ARTICLE | Product Development
Modalities merge into new platforms at SITC 2022
Meeting highlights new platforms combining pieces of cell therapy, bispecific, oncolytic virus and cytokine peptide technologies
November 12, 2022 1:23 AM UTC
Two new modalities may be better than one when designing cancer therapies, based on an emerging trend showcased at SITC 2022. The conference’s preclinical presentations suggest the next wave of immuno-oncology drugs may be hybrids of the modalities that have transformed the treatment landscape over the past decade.
Blending those modalities appears to be one way companies aim to address the field’s biggest challenges...